The latest announcement is out from Microbot Medical (MBOT).
Microbot Medical Inc. has announced FDA approval to commence a significant clinical trial for its LIBERTY® Endovascular Robotic Surgical System, signaling a major step forward in medical robotics. The company has partnered with a top academic medical center and aims to include more prestigious institutions in this groundbreaking study. While they embark on human trials, they’ll also complete necessary biocompatibility testing. However, investors should note that these forward-looking statements carry risks, and actual outcomes may differ, with the company not obligated to update these statements.
For detailed information about MBOT stock, go to TipRanks’ Stock Analysis page.
